<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170222</url>
  </required_header>
  <id_info>
    <org_study_id>M02-007</org_study_id>
    <nct_id>NCT00170222</nct_id>
  </id_info>
  <brief_title>Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <brief_summary>
    <textblock>
      The role of antibiotic therapy in patients with COPD remains controversial. While the outcome&#xD;
      of several clinical trials is in favour of antibiotics, the quality of these studies in&#xD;
      insufficient. In this study the efficacy of doxycycline is compared to placebo. All&#xD;
      concommitant treatment (steroids, bronchodilator therapy, physiotherapy) is standardized.&#xD;
&#xD;
      The investigators hypothesize that patients with an acute exacerbations will have a better&#xD;
      outcome when treated with antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy at the end of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure at follow up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbation</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute exacerbation of COPD type I or II according to GOLD&#xD;
&#xD;
          -  Ability to perform lung function tests&#xD;
&#xD;
          -  Ability to take oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, or women of childbearing age not using an acceptable&#xD;
             method of contraception.&#xD;
&#xD;
          -  Pretreatment ( &gt; 24 hours) with an antibiotic for the present exacerbation.&#xD;
&#xD;
          -  Pretreatment with corticosteroids (&gt;30 mg for more than 4 days) for the present&#xD;
             exacerbation.&#xD;
&#xD;
          -  Progression or new radiographic abnormalities on the chest X-ray.&#xD;
&#xD;
          -  Severe exacerbation that required mechanical ventilation.&#xD;
&#xD;
          -  History of bronchiectasis&#xD;
&#xD;
          -  Recent or unresolved lung malignancy.&#xD;
&#xD;
          -  Other disease likely to require antibiotic therapy.&#xD;
&#xD;
          -  Significant gastrointestinal or other conditions that may affect study drug&#xD;
             absorption.&#xD;
&#xD;
          -  Class III or IV congestive heart failure or stroke.&#xD;
&#xD;
          -  Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction&#xD;
             etc. and the use of immunosuppressive drugs (&gt;30 mg prednisolone maintenance dose or&#xD;
             equivalent for more than 4 weeks).&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Tuberculosis.&#xD;
&#xD;
          -  Impaired renal function (creatinine clearance &lt; 20 ml/min).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes MA Daniels, drs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmo Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominic Snijders, drs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmo Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-holland</state>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 26, 2008</last_update_submitted>
  <last_update_submitted_qc>September 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2008</last_update_posted>
  <keyword>Acute bronchitis</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

